



Claims

1. Compound 5-({6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxypyridin-1(2*H*)-yl]-3-methylhexanoyl}amino)pyrazolo[1,5-*a*]pyridine-3-carboxamide of the formula (I)




5 or one of the salts thereof, solvates thereof or solvates of the salts thereof.

2. Compound 5-({6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxypyridin-1(2*H*)-yl]-3-methylhexanoyl}amino)pyrazolo[1,5-*a*]pyridine-3-carboxamide trifluoroacetate according to Claim 1 of the formula (Ia)



- 10 3. Compound 5-(({2*S*)-6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxypyridin-1(2*H*)-yl]-3-methylhexanoyl}amino)pyrazolo[1,5-*a*]pyridine-3-carboxamide according to Claim 1 of the formula (Ib)



or one of the salts thereof, solvates thereof or solvates of the salts thereof.

4. Compound according to any of Claims 1 to 3 for the treatment and/or prophylaxis of diseases.
5. Use of a compound according to any of Claims 1 to 3 for producing a medicament for the treatment and/or prophylaxis of diseases.
6. Use of a compound according to any of Claims 1 to 3 for producing a medicament for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders.
7. Medicament according to Claim 5 for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders.
8. Compound according to any of Claims 1 to 3 for use in a method for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders using a therapeutically effective amount of a compound according to the invention.
9. Compound according to any of Claims 1 to 3 for use in plasma prekallikrein (PPK) or plasma kallikrein (PK) containing biological samples to prevent disturbing effects caused by the turnover of physiological and artificial substrates by PK.